Burosumab

Burosumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	FGF 23
Clinical data
Trade names	Crysvita
Other names	KRN23
ATC code	M05BX05 (WHO) ;
Identifiers
CAS Number	1610833-03-8;
ChemSpider	none;
UNII	G9WJT6RD29;
KEGG	D10913;
Chemical and physical data
Formula	C6388H9904N1700O2006S46
Molar mass	144090.15 g·mol−1

Burosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2][3] Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018.[4] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[4]

This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin.[5]

While burosumab is effective for the treatment of X-linked hypophosphatemia, the National Institute for Health and Care Excellence in England and Wales initially raised concerns regarding the incremental cost-effectiveness of the new treatment[6] but the drug is available through a simple discount scheme. [7]

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Burosumab, American Medical Association.
World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2): 255.
"Burosumab (KRN23) for X-Linked Hypophosphatemia (XLH)" (PDF). n.d. Archived from the original (PDF) on 2018-04-18. Retrieved 2018-04-18.
"FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia" (Press release). FDA. 17 April 2018.
"Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia" (Press release). Kyowa Kirin. 4 September 2013. Retrieved 2018-04-17.
"U.K. cost watchdogs turn away rare disease med Crysvita".
"1 Recommendations | Burosumab for treating X-linked hypophosphataemia in children and young people | Guidance | NICE". www.nice.org.uk. Retrieved 2019-06-14.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Burosumab, American Medical Association.

[2] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2): 255.

[Slidebackground-3] "Burosumab (KRN23) for X-Linked Hypophosphatemia (XLH)" (PDF). n.d. Archived from the original (PDF) on 2018-04-18. Retrieved 2018-04-18.

[:0-4] "FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia" (Press release). FDA. 17 April 2018.

[5] "Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia" (Press release). Kyowa Kirin. 4 September 2013. Retrieved 2018-04-17.

[6] "U.K. cost watchdogs turn away rare disease med Crysvita".

[7] "1 Recommendations | Burosumab for treating X-linked hypophosphataemia in children and young people | Guidance | NICE". www.nice.org.uk. Retrieved 2019-06-14.